Related Experiment Videos
Surgery for pulmonary metastases. The Heidelberg experience
I Vogt-Moykopf1, S Krysa, H Bülzebruck
1Surgical Department, Hospital for Thoracic Diseases, Heidelberg, Germany.
Chest Surgery Clinics of North America
|February 1, 1994
Summary
Surgical treatment for pulmonary metastases offers a 33% 5-year survival rate, aligning with global standards. Careful patient selection using prognostic factors is crucial to optimize surgical outcomes and avoid undertreatment or overtreatment.
Area of Science:
- Oncology
- Thoracic Surgery
- Cancer Research
Background:
- Surgical resection of pulmonary metastases is a key component of multidisciplinary cancer care.
- Established international standards exist for survival rates following this procedure.
Purpose of the Study:
- To evaluate the survival rates associated with surgical treatment of pulmonary metastases.
- To determine the impact of curative versus non-curative operations on survival.
- To identify prognostic factors for optimizing surgical indications.
Main Methods:
- Analysis of actuarial survival rates in patients undergoing surgery for pulmonary metastases.
- Stratification of survival data based on the curability of surgical operations (macroscopically radical vs. non-radical).
- Review of prognostic factors relevant to surgical decision-making.
Main Results:
- The overall 5-year actuarial survival rate was 33%, consistent with international benchmarks.
- For patients with potentially curative (macroscopically radical) operations, the 5-year survival rate was 38%.
- Data on the curative intent of surgeries are infrequently reported.
Conclusions:
- Surgical treatment for pulmonary metastases yields survival rates comparable to international standards.
- Distinguishing between curative and non-curative resections is vital for accurate outcome assessment.
- Consideration of prognostic factors is essential for appropriate patient selection, minimizing undertreatment and overtreatment risks.